LONDON (Reuters) -Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal. Last ...
BioNTech (NASDAQ:BNTX), the partner of Pfizer (NYSE:PFE) for Comirnaty COVID-19 shot, reported its Q4 2023 financials on Wednesday, in the black, despite a ~65% drop in revenue driven by sliding ...
(Reuters) -Germany's BioNTech announced on Monday a partnership with a global coalition for up to $90 million in funding to support the development of mpox vaccine candidates. BioNTech would initiate ...
BioNTech (NASDAQ:BNTX) announced Tuesday that its mRNA-based cancer therapy BNT111, in combination with Regeneron’s (NASDAQ:REGN) anti-PD-1 therapy, Libtayo (cemiplimab), succeeded in a Phase 2 trial ...
J.P. Morgan has downgraded BioNTech SE (NASDAQ:BNTX), acknowledging the company's substantial cash reserves and limited downside potential. The analysts Jessica Fye, Na Sun, and Nick Lenard expressed ...
The minimum condition for the offer has been satisfied, with 184,071,410 shares of CureVac, representing approximately 81.74% of CureVac’s issued and outstanding shares, tendered prior to the ...
(Reuters) -Pfizer Inc said on Thursday it sold a part of its stake in German drugmaker BioNTech SE, more than five years after both firms formed an alliance that yielded a vaccine to combat the deadly ...
(Reuters) - Germany's BioNTech said on Monday that it signed a deal with Chinese biotech company DualityBio to co-develop and commercialize two cancer antibody drug candidates. DualityBio will receive ...
(Reuters) -BioNTech has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University of Pennsylvania over the payment of royalties related to its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback